Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a research note issued on Thursday. They currently have a GBX 220 ($2.85) target price on the stock. Peel Hunt’s target price indicates a potential upside of 39.68% from the company’s previous close.

Separately, Liberum Capital reiterated a “buy” rating and set a GBX 310 ($4.02) target price on shares of Shield Therapeutics PLC in a research note on Monday, March 13th.

Shares of Shield Therapeutics PLC (LON STX) remained flat at GBX 157.50 during trading on Thursday. 2,500 shares of the stock traded hands. The stock’s market cap is GBX 182.86 million. The stock’s 50-day moving average is GBX 165.04 and its 200-day moving average is GBX 167.99. Shield Therapeutics PLC has a 1-year low of GBX 149.50 and a 1-year high of GBX 177.00.

WARNING: This news story was first posted by American Banking News and is the property of of American Banking News. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/07/09/shield-therapeutics-plcs-stx-buy-rating-reiterated-at-peel-hunt.html.

About Shield Therapeutics PLC

Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.

Receive News & Ratings for Shield Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.